Alto neuroscience inc ANRO.US 總覽分析
ANRO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ANRO 近期報酬表現
-3.69%
Alto neuroscience inc
1.99%
同產業平均
-0.64%
S&P500
與 ANRO 同產業的標的表現
- NTLA Intellia therapeutics inc價值 4 分趨勢 3 分波段 5 分籌碼 3 分股利 1 分查看更多
ANRO 公司資訊
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. Through insights derived from the Company's scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. The advanced programs are supported by prospectively replicated evidence of clinical activity in biomarker-characterized populations.